
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1112 | 1058 | 1080 | 1347 | 1680 | 1597 |
Fund Return | 11.16% | 5.83% | 7.97% | 10.43% | 10.93% | 4.79% |
Place in category | 389 | 361 | 598 | 487 | 560 | 526 |
% in Category | 15 | 17 | 27 | 25 | 35 | 53 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
AllianzIncome Growth AM H2EUR | 53.72B | 4.95 | 6.82 | 5.07 | ||
AllianzIncome Growth P H2EUR | 53.72B | 5.33 | 7.39 | 5.71 | ||
AllianzIncome Growth A H2EUR | 53.72B | 4.96 | 6.81 | 5.08 | ||
AllianzIncome Growth IT H2EUR | 53.72B | 5.29 | 7.52 | 5.80 | ||
AllianzIncome Growth CT H2EUR | 53.72B | 4.51 | 5.96 | 4.26 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Eleva Euro Slct Class R EUR Acc | 7.64B | 9.12 | 12.23 | 7.41 | ||
Eleva Euro Slct Class I EUR Acc | 7.64B | 9.13 | 12.27 | 7.51 | ||
Eleva Euro Slct Class A1 EUR Acc | 7.64B | 8.74 | 11.66 | 6.90 | ||
Eleva Euro Slct Class A2 EUR Acc | 7.64B | 8.42 | 11.19 | 6.39 | ||
European Growth Fund Y Acc EUR | 236.44M | 7.61 | 11.82 | 5.35 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Allianz Eurp Eq pwrd by Artfcl IntlgcWT€ | LU2397364675 | 6.55 | - | - | |
ASML Holding | NL0010273215 | 2.72 | 629.00 | +1.91% | |
SAP | DE0007164600 | 2.57 | 230.625 | +1.49% | |
Novartis | CH0012005267 | 2.54 | 102.10 | +0.89% | |
Roche Holding Participation | CH0012032048 | 2.13 | 265.60 | +1.37% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Buy | Strong Buy |
Technical Indicators | Strong Sell | Sell | Strong Buy |
Summary | Strong Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review